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Purpose: To investigate magnetic resonance imaging (MRI) features for differentiating ovarian endometrioid
adenocarcinoma (OEC) from high-grade serous adenocarcinoma (HGSC).
Materials and methods: Twenty-three patients with 25 OECs and 93 patients with 139 HGSCs confirmed by
surgery and pathology underwent conventional MRI and diffusion-weighted imaging (DWI). The MRI features of the
tumors, including laterality, size, shape, configuration, signal intensity, ADC value of solid component, enhancement,
ascites, synchronous primary cancer (SPC) of the ovary and endometrium, and clinical stage, were evaluated and
compared between two groups.
Results: The following characteristics were significantly more common for OECs than HGSCs: unilateral (91.3% vs
50.5%, P < 0.001), larger mass (80.0% vs 48.2%, P = 0.005), round or oval shape (64.0% vs 17.3%, P < 0.001), mainly
cystic with mural nodules or papillary projections (72.0% vs 18.7%, P < 0.001), cystic component with homogeneous
iso- or hyperintensity on T1WI (82.6% vs 4.3%, P < 0.001), moderate enhancement (52.0% vs 26.6%, P = 0.011), no or
mild ascites (91.3% vs 57.0%, P = 0.002), and SPC (43.5% vs 4.3%, P < 0.001). The ADC value of the solid component
was higher in OECs (0.979 ± 0.197 × 10−3 mm2/s) than in HGSCs (0.820 ± 0.112 × 10−3 mm2/s) (P = 0.002). When a
mainly cystic mass with mural nodules or papillary projections was associated with any one of homogeneously
iso- or hyperintense cystic component on TIWI, a relatively higher ADC value and SPC, the sensitivity, specificity,
accuracy, and positive and negative predictive values for characterizing OEC were 87.0%, 93.5%, 92.2%, 76.9%, and
96.7%, respectively.
Conclusions: Conventional MRI combining DWI is helpful for differentiating OECs from HGSCs.
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When an adnexal mass is suspected to be an epithelial
ovarian carcinoma by magnetic resonance imaging
(MRI), the primary concern of clinicians is that the pa-
tient has a high-grade serous adenocarcinoma (HGSC),
which is the most frequent epithelial carcinoma and
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unless otherwise stated.endometrioid carcinoma (OEC), the second most com-
mon type of epithelial carcinoma, accounts for 10% of
all epithelial ovarian malignancies, shares similar mor-
phologic features to HGSC [2]. Previous studies have
indicated that there are different risk factors, origins,
genetic alterations, biological behaviors, clinicopatho-
logical characteristics and chemotherapy sensitivities be-
tween OEC and HGSC. Clincally, patients with OECs
are more likely to have early stage disease and generally
have a favorable prognosis [3-6]. However, few studies
have focused on the imaging of OEC [7]. As a result, the
imaging features of OEC have not been completelyis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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weighted imaging (DWI) have not been investigated for
their ability to differentiate between OEC and HGSC.
Preoperative imaging differentiation of OEC from HGSC
will be helpful for the management of patient with OEC,
because a conservative fertility-sparing surgery can be
considered for patients with early-stage OEC who wish to
preserve fertility [8]. Therefore, this retrospective study
evaluated conventional MRI and DWI for distinguishing
OEC from HGSC to improve the preoperative charac-
terization and surgical planning of these two distinctive
types of ovarian cancers.
Methods
Clinical data
The institutional ethical board (Jinshan Hospital, Shang-
hai Medical College, Fudan University) approved this
retrospective study, and informed consent was waived.
Between September, 2010 and October, 2014, we
searched for the data of patients with OEC at our hospi-
tals information system and picture achiving and com-
munication system. A total of 25 patients with OEC
confirmed by surgery and pathology were found. We
excluded 2 patients with metastatic OEC. The remaining
23 patients with 25 OECs were reviewed in this study.
The mean age of the patients was 54 ± 9 years (range,
32–81 years). As a comparison, 93 patients with 139
HGSCs were served as a control group from 126 surgi-
cally and pathologically confirmed cases of HGSC at the
same period and database. We excluded 15 patients who
received chemotherapy before MR scanning, 8 patients
who were performed on a 3.0 T MR scanner, 6 patients
with poor image quality and 4 patients without the
administration of intravenous contrast. Their mean age
was 55 ± 9 years (range, 35–78 years), which was not sig-
nificantly different from the mean age of patients with
OEC (P = 0.508). The diagnosis of SPC was established
according to the pathological criteria proposed by Singh
[9]. Twelve patients presented with abdominal pain and
swelling; eight patients presented with vaginal bleeding;
two patients were asymptomatic and were diagnosed
during a routine physical examination; and the last
patient presented with an abdominal mass. All patients
underwent surgery within 2 weeks after completing the
MRI scan.
MRI scanning
MR imaging was performed using a 1.5-T scanner
(Avanto or Espree, Siemens, Erlangen, Germany) with a
phased-array abdominal coil. The patients laid in a
supine positon and breathed freely during acquisition.
The sequences were obtained as follows: axial spin echo
(SE) T1-weighted imaging (T1WI) [time of repetition
(TR)/time of echo (TE), 340 ms/10 ms]; axial turbo SET2-weighted imaging (T2WI) with and without fat satur-
ation (TR/TE, 8000 ms/83 ms and 4000 ms/98 ms,
respectively); and sagittal and coronal turbo SE T2WI
(TR/TE, 8000 ms/98 ms). Axial DWI (19 patients with
20 OECs and 83 patients with 124 HGSCs) was obtained
with echo planar imaging (TR/TE, 3200 ms/83 ms) and
b factors of 0 and 1000 s/mm2. Contrast-enhanced flash
2D T1WI with fat saturation (TR/TE, 196 ms/2.9 ms) was
performed in the axial, sagittal and coronal planes immedi-
ately after the intravenous administration of Gadopentetate
dimeglumine (Magnevist; Bayer Schering, Guangzhou,
China) at a dose of 0.2 mmol/kg of body weight and a
rate of 2–3 ml/s. The scanning parameters were as follows:
5-mm slice thickness, 1.2-mm gap, 256–320 × 256–320
matrix, 250–296 mm× 250–340 mm field of view and four
excitations. The scanning range was from the inferior
pubic symphysis to the renal hilum and extended beyond
the dome of the tumor in cases with huge masses.
Image analysis
The MR images were reviewed independently by two
radiologists (H.M.L and J.W.Q) with 7 years and 30 years
of experience in abdominal imaging, respectively, and
were blinded to the original reports (radiology, surgery
and pathology). Any discrepancies were resolved by
consensus. The following features of the tumors were
evaluated: (a) uni- or bilaterality (both ovaries having
similarly sized tumors, which indicates the simultaneous
development of primary malignancies), size and shape;
(b) mass configuration (mainly cystic, less than one-third
solid component; mixed cystic-solid, one- to two-thirds
solid component; and solid, more than two-thirds solid
component); (c) signal intensity (hypo-, iso-, and hyperin-
tensity, referring to the signal of the outer myometrium in
solid components; to the signals of muscle and iliac mar-
row in cystic components on T1WI and T2WI; and to the
signals of small intestine and iliac vessel on DWI and
ADC maps, respectively); (d) enhancement (mild, moder-
ate or marked by referencing those of the junctional zone
and outer myometrium); (e) amount of ascites (none,
mild, moderate, and severe) (f) associated findings (uterine
endometrial carcinoma); and (g) apparent diffusion coeffi-
cient (ADC) value as measured on ADC maps, a circular
region of interest (ROI) of at least 1 cm2 was placed at
targeted areas with the possibly lowest ADC values in the
solid components of the tumor, by referring to conven-
tional MR imagings and avoiding areas such as haemor-
rhage, necrosis and major vascular structures. At least
three measurements were obtained and averaged.
Statistical analysis
SPSS 16.0 for Windows (SPSS Inc., Chicago, IL, USA) was
used for the statistical analysis. The differences between
OECs and HGSCs in laterality, shape, mass configuration,
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stage were compared using a Pearson chi-square test.
The differences in age, mass size, and ADC values between
the two groups were compared using the two independent-
sample Student t-test. A P-value less than 0.05 was
considered statistically significant. Receiver operating char-
acteristic (ROC) curve analysis was used to determine a
cut-off value for differentiating OECs and HGSCs.
Results and discussion
The maximum diameters of the OECs ranged from 3.7 to
22.5 cm (mean 11.1 ± 4.9 cm), and those of the HGSCs
ranged from 2.5 to 16.8 cm (8.1 ± 3.4 cm) (P = 0.005). The
median size of the tumors was 9.9 cm in OECs versusTable 1 MRI morphological features of OEC versus HGSC









Cystic with mural nodules or papilla 18 (72.0%)
Mixed cystic-solid 5 (20.0%)
Solid 2 (8.0%)
SI of solid component on T1WI
Iso-/hypointense 24 (96.0%)
Mainly iso- with hyperintense 1 (4.0%)
SI of solid component on T2WI
Isointense 3 (12.0%)
Heterogeneous hyperintense 22 (88.0%)
SI of cystic component on T1WI
Homogeneous hypointense 4 (17.4%)
Homogeneous iso-/hyperintense 19 (82.6%)
Mainly hypo- with iso-/hyperintense 0
SI of cystic component on T2WI
Homogeneous hyperintense 18 (78.3%)





None or mild 21 (91.3%)
Moderate or severe 2 (8.7%)
SPC^ 10 (43.5%)
SI: signal intensity; *Mixed signal means that two or more signals within the tumors7.6 cm in HGSCs. A bilateral mass was found in 2 OEC
patients and 46 HGSC patients (P < 0.001). According to
the International Federation of Gynecology and Obstetrics
(FIGO) staging system, 19 patients with OECs were at
stage I (82.6%), 3 were at stage II (13.0%), and 1 was at
stage III (4.4%). Pathologically, 14 OECs were grade 1, 8
were grade 2, and 1 was grade 3. For the HGSC group, 6
patients were at stage I (6.4%), 9 were at stage II (9.7%), 73
were at stage III (78.5%), and 5 was at stage IV (5.4%).
There was a statistically significant difference in the num-
ber of patients at different stages of disease between the
two groups (P < 0.000).
The MRI features of OEC and HGSC are summarized
































. ^ numbers for 23 patients with OEC and 93 patients with HGSC.
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The mass configuration was mainly cystic with mural
nodules or papillary projections in 18 of 25 (72.0%)
OECs versus 26 of 139 (18.7%) HGSCs (P < 0.001). The
signal of the cystic component was homogeneously
iso- or hyperintense on TIWI in 19 of 23 (82.6%) OECs
versus 3 of 69 (4.3%) HGSCs (P < 0.001) (Figures 1, 2
and 3). The solid component showed a moderate en-
hancement in 13 of 25 (52.0%) OECs versus 37 of 139
(26.6%) HGSCs (P = 0.011). No or mild ascites were ob-
served in 21 of 23 (91.3%) OECs versus 53 of 93 (57.0%)
HGSCs (P = 0.002) (Figures 4 and 5). SPC was observed
in 10 of 23 (43.5%) OECs versus 4 of 93 (4.3%) HGSCs
(P < 0.001) (Figure 1). Other features, such as the signal
intensity of the solid component on T1WI, T2WI, and the
signal intensity of the cystic component on T2WI were not
significantly different between the two groups (P > 0.05).
On DWI, the solid component showed hyperintensity
in 17 of 20 (85.0%) OECs and isointensity in the remaining
3 (15.0%), while for HGSCs, the solid component showed
hyperintensity in 111 of 116 (95.7%) and isointensity in 5
(4.3%) (P = 0.173). The mean ADC value of the solid com-
ponent was (0.979 ± 0.197) × 10−3 mm2/s in 20 of 25 OECs
versus (0.820 ± 0.112) × 10−3 mm2/s in 116 of 139 HGSCs
(P = 0.002) (Figures 1, 3, 4 and 5). ROC curve analysis
yielded an optimal ADC value threshold of 0.971 ×
10−3 mm2/s for differentiating OECs from HGSCs, with a
sensitivity of 55.0%, a specificity of 94.0% and an accuracy
of 88.2%.Figure 1 A 50-year-old woman with right-sided OEC. The tumor
appears as a mainly cystic mass with a large mural nodule. The
cystic component (crossstar) shows slight hyperintensity on axial
T1WI (a), homogeneous hyperintensity on axial T2WI with fat
suppression (b), no enhancement on contrast-enhanced T1WI with
fat suppression (c), isointensity on DWI (d). The mural nodule
(arrow) demonstrates isointensity (a), heterogenous hyperintensity
(b), marked enhancement (c) and hyperintensity (d) with an ADC
value of 1.030 × 10−3 mm2/s, respectively. Synchronous uterine
endometrial carcinoma (arrowhead) shows mild enhancement on
contrast-enhanced T1WI and hyperintensity on DWI.The diagnostic performance of the different MRI fea-
tures for differentiating OEC from HGSC are listed in
Table 2. When a mainly cystic mass with mural nodules
or papillary projections was associated with any one of
homogeneously iso- or hyperintense cystic component on
TIWI, a higher ADC value, and SPC, the sensitivity, speci-
ficity, accuracy, positive and negative predictive values for
characterizing OEC were 87.0%, 93.5%, 92.2%, 76.9%, and
96.7%, respectively.
During the past decade, there has been strong interest
in type-specific treatment of epithelial ovarian carcin-
oma, and considerable advances have been achieved in
the understanding and differentiation of the five types
of ovarian cancers (high-grade serous adenocarcinoma,
endometrioid carcinoma, clear cell carcinoma, mucinous
carcinoma, low-grade serous adenocarcinoma) [10,11].
Ovarian HGSCs and OECs are two of the most frequent
types of epithelial ovarian carcinomas. Studies have indi-
cated that most OECs are diagnosed at an early stage,
have a low histologic grade, respond well to chemother-
apy, and consequently, have a lower recurrence rate and
a better survival compared with HGSCs [5]. Further-
more, studies have suggested that the fertility-preserving
surgery has a low currence rate and is safe for the pa-
tient with stage I epithelial ovarian carcinoma. There is
no difference in the overall survival compared with the
radical surgery [12-15]. In contrast, patients with HGSC
need radical surgical staging and cytoreduction [8].
Therefore, discriminating OEC from HGSC is essential
for preoperative surgical planning, especially in stage I
patients who wish to preserve fertility and/or female
endocrine functions.
The present MRI study showed that OECs were sig-
nificantly different from HGSCs in laterality, size, shape,
configuration, signal intensity, enhancement, ADC value,
SPC, clinical stage and ascites. OEC commonly appeared
as a large, unilateral, round or oval cystic mass with
mural nodules or papillary projections, homogeneous
iso- or hyperintensity on T1WI in the cystic component,
and moderate enhancement and relatively higher ADC
values in the solid component. OEC was commonly asso-
ciated with SPC and was diagnosed at an early stage. In
contrast, HGSC was typically a moderately sized, irregular
solid or mixed cystic-solid mass with marked enhance-
ment and a lower ADC value, more common bilaterality
and moderate to severe ascites. Although some features
had low diagnostic specificity, four features, a cystic mass
with mural nodules or papillary projections, homoge-
neously iso- or hyperintense cystic component on T1WI,
higher ADC value and SPC, have a high specificity for
OEC. Those four features yielded a sensitivity, specificity,
accuracy, positive and negative predictive values for char-




Figure 2 A 32-year-old woman with left-sided OEC. Axial and sagittal T2WI (a, c) demonstrate a mainly cystic mass with multiple mural nodules
(arrows). Axial and sagittal contrast-enhanced T1WI with fat suppression (b, d) show that the nodules are moderately enhanced.
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atypical endometriosis is a precursor lesion for OEC.
OEC associated endometriosis is found in 20%-40% of
cases [16]. In contrast, most ovarian HGSCs are con-
firmed to be derived from the tubal intraepithelial lining
[17], and only 7% of cases have a history of ovarian
endometriosis [18]. In our study, only 13.0% (3/23) of
OECs were shown histopathologically to have arisen
from an endometriotic cyst, an incidence lower than that
of a previous study (33.3%) [7]. A possible explanation
for this result is insufficient sampling due to the study
not being pathogenesis-oriented [19].
A previous study showed that 33.3% of OECs were
cystic, and the remaining 66.7% were mainly solid, which
was inconsistent with our findings [7]. Selection bias anda
Figure 3 A 53-year-old woman with left-sided OEC. Contrast-enhanced T1
mural nodules (arrow), which show a marked enhancement (a) and a hypemisdiagnosis are the possible causes because research has
found that 50 of 176 (28%) formerly diagnosed OECs are
actually HGSCs [20]. The cystic component displayed
homogeneous iso- or hyperintensity on T1WI in 82.6%
(19/23) of OECs versus 4.3% of HGSCs and was another
important differentiating feature. The iso- or hyperinten-
sity on T1WI signifies bloody cystic content, which may
imply OEC is derived from endometriosis [21].
In our study, almost all OECs and HGSCs demonstrated
high signal in the solid component on DWI. The mean
ADC value of the solid component was (0.979 ± 0.197) ×
10−3 mm2/s in OECs versus (0.820 ± 0.112) × 10−3 mm2/s
in HGSCs, and this difference was statistically significant.
An optimal ADC value threshold of 0.971 × 10−3 mm2/s
yielded a sensitivity, specificity and accuracy of 55.0%,b c
WI with fat suppression (a) demonstrates a mainly cystic mass with
rintensity on DWI (b) with an ADC value of 1.174 × 10−3 mm2/s(c).
a b 
c d 
Figure 4 A 67-year-old woman with left-sided HGSC. Axial T2WI (a) demonstrates a solid mass (short arrow) with an irregular shape and a large
volume of ascites (long arrow). The mass is markedly enhanced with irregular areas of necrosis (asterisk) on contrast-enhanced T1WI with fat
suppression (b), hyperintensity on DWI (c) and hypointensity on ADC map with an ADC value of 0.682 × 10−3 mm2/s (d).
Li et al. Journal of Ovarian Research  (2015) 8:26 Page 6 of 894.0% and 88.2%, respectively, for differentiating OECs
from HGSCs, In our study, the solid component in OECs
was mainly mural nodules or papillary projections, which
were reported to have relatively low malignant potential
[22]. Histopathologically, the mural nodules or papillary
projections had a loose structure with fewer tumor cells, aa 
c 
Figure 5 A 57-year-old woman with bilateral HGSC. Axial T2WI (a) demons
cystic-solid mass (short arrow) in the left-sided ovary, which have an irregu
of the masses and peritoneal nodules (arrows) are enhanced markedly on
DWI (c) and hypointensity on ADC map (d) with an ADC value of 0.759 × 1fibrous axis, and interstitial edema; this explains the higher
ADC value of OECs [23]. In contrast, the solid component
in HGSCs was mainly a solid mass that histopathologically
contained substantial tumor cells resulting in restricted
movement of water molecules and, consequently, a lower
ADC value.b 
d 
trates a solid mass (long arrow) in the right-sided ovary and a mixed
lar shape. A large volume of ascites is observed. The solid components
contrast-enhanced T1WI with fat suppression (b), hyperintensity on
0−3 mm2/s (left) and 0.782 × 10−3 mm2/s (right).
Table 2 Diagnostic performance of MRI for differentiating OEC from HGSC
MRI features Sensitivity Specificity Accuracy PPV(%) NPV(%)
Mass size (≥7.8 cm) 80.0(20/25) 51.8(72/139) 56.1(92/164) 23.0(20/87) 93.5(72/77)
Unilateral 91.3(21/23) 49.5(46/93) 57.8(67/116) 30.9(21/68) 95.8(46/48)
Round/Oval shape 64.0(16/25) 82.7(115/139) 79.9(131/164) 40.0(16/40) 92.7(115/124)
Mainly cystic mass 72.0(18/25) 81.3(113/139) 79.9(131/164) 40.9(18/44) 94.2(113/120)
Homogeneous iso-/hyperintensity* 82.6(19/23) 95.7(66/69) 92.4(85/92) 86.4(19/22) 94.3(66/70)
Moderate enhancement 52.0(13/25) 73.4(102/139) 70.1(115/164) 26.0(13/50) 89.5(102/114)
Ascites(none or mild) 91.3(21/23) 43.0(40/93) 52.6(61/116) 28.4(21/74) 95.2(40/42)
SPC 43.5(10/23) 95.7(89/93) 85.3(99/116) 71.4(10/14) 87.3(89/102)
ADC value^ 55.0(11/20) 94.0(109/116) 88.2(120/136) 61.1(11/18) 92.4(109/118)
PPV: positive predictive value; NPV: negative predictive value; *the signal intensity of cystic component on T1WI; ^ ADC value of solid component
(≥0.971 × 10−3 mm2/s), ADC values of solid components are measured and averaged in 20 OECs and 116 HGSCs.
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cases have two or more synchronous primary genital
tract carcinomas [8]. Approximately 10% of women
with ovarian cancer will be found to have synchronous
endometrial cancer, and approximately 5% of women
with endometrial cancer harbor simultaneous ovarian
cancer [24]. Synchronous OEC and endometrial cancer
accounts for 50-70% of SPC [8,25]. On MR imaging,
endometrial cancer of SPC often displayed superficial or
no myoinvasion. In the present study, the synchronous
primary endometrial carcinomas were found in 43.5%
of OEC patients versus 4.3% of HGSC patients, which
indicated high specificity for OEC. However, other
studies found synchronous primary endometrial carcin-
omas in 16% of OEC patients [7].
Our study had several limitations. First, only imaging
features of a limited number of patients were evaluated.
Therefore, larger samples are necessary to confirm the
value of these features for diagnosing OEC. Second, due
to the retrospective design of our study, a selective bias
was inevitable. Third, a correlation analysis of MRI
features with pathology was not performed.
Conclusions
In conclusion, our preliminary study demonstrates
that a large, round or oval, mainly cystic mass with
moderately enhanced mural nodules or papillary pro-
jections, a homogeneously iso- or hyperintense cystic
component on TIWI, a relatively higher ADC value
in the solid component and, commonly, SPC are
features that help to differentiate OEC from HGSC.
Although the diagnostic performance of any feature
alone is not sufficient for diagnosis, the combination
of the feature of a mainly cystic mass with mural
nodules or papillary projections with any one of the
following features: homogeneously iso- or hyperin-
tense cystic component on TIWI, a relatively higherADC value and SPC, yields high sensitivity, specificity
and accuracy for identifying OEC.
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